Biogen, UCB Reveal Details Behind Surprise Late-Stage Win in …
19 小时之前 · Biogen and UCB on Tuesday provided more details regarding their unexpected late-stage victory in the Phase III PHOENYCS GO trial and plotted out a potential regulatory path for their drug candidate dapirolizumab pegol in systemic lupus erythematosus.. In September 2024, the partners announced that PHOENYCS GO …
UCB And Biogen: Dapirolizumab Pegol Meets Primary Endpoint In …
1 天前 · (RTTNews) - UCB and Biogen Inc. (BIIB) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol, a Fc-free anti-CD40L drug candidate, showing significant ...
Samsung Bioepis, Biogen Get European Commission ... - Markets …
1 天前 · (RTTNews) - Samsung Bioepis Co., Ltd. and Biogen Inc. (BIIB) Monday announced that the European Commission (EC) has approved Opuviz, a biosimilar to Regeneron Pharmaceuticals' Aflibercept. Opuviz ...
News - Biogen
2024年10月30日 · Biogen Reports Third Quarter 2024 Results. Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases. Biogen Appoints Daniel Quirk, MD, …
Biogen’s stock rises after E.U. regulator reverses negative view of ...
5 天之前 · Biogen’s stock rose 1% Thursday, after Europe’s pharmaceutical regulator issued a positive opinion on the Alzheimer’s disease drug that the company developed with Japanese partner Eisai ...
Biogen Announces Positive Topline Results from Study of Higher …
2024年9月4日 · Positive study demonstrates the potential for investigational higher dose nusinersen regimen to advance the treatment of SMA; Biogen plans to submit for regulatory approval of this investigational dose regimen; Higher dose nusinersen regimen showed statistically significant improvement compared to a prespecified matched sham control group
Biogen Raises Forecast as Alzheimer’s Drug Leqembi Shows Signs …
2024年10月30日 · (Bloomberg) -- Biogen Inc. raised its annual earnings guidance after reporting better-than-expected third-quarter sales and profit, driven by ongoing cost-cutting measures and the strong performance of its new Alzheimer’s treatment.
Biogen to Realign Resources for Alzheimer's Disease Franchise
CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced plans to reprioritize its resources in Alzheimer’s disease (AD), a strategic therapeutic area expected to drive near and long-term growth.
Biogen discontinues Alzheimer’s medication Aduhelm - CNN
2024年1月31日 · The Alzheimer’s medication Aduhelm is being discontinued by drugmaker Biogen as it shifts resources to its other Alzheimer’s medication, Leqembi, and developing other treatments, the company...
Biogen Inc. (BIIB) Latest Stock News & Headlines - Yahoo Finance
Get the latest Biogen Inc. (BIIB) stock news and headlines to help you in your trading and investing decisions.